Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma (Q39820294)

14 September 2017

title

Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma (English)

1 reference

local neoplasm recurrence

14 September 2017

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

1

G. Minniti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

7

M. F. Osti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

author name string

V. Armosini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

M. Salvati

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

G. Lanzetta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

P. Caporello

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

M. Mei

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

R. Enrici Maurizi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21052773

21 August 2024

language of work or name

1 reference

5 November 2010

1 reference

full work available at URL

14 September 2017

http://link.springer.com/content/pdf/10.1007/s11060-010-0446-8.pdf

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1007/S11060-010-0446-8

http://link.springer.com/article/10.1007/s11060-010-0446-8/fulltext.html

21 August 2024

1 reference

https://api.crossref.org/works/10.1007/S11060-010-0446-8

http://link.springer.com/content/pdf/10.1007/s11060-010-0446-8

21 August 2024

1 reference

DOI

https://api.crossref.org/works/10.1007/S11060-010-0446-8

Journal of Neuro-Oncology

21 August 2024

published in

1 reference

14 September 2017

volume

103

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

683-691

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Reoperation for recurrent glioblastoma and anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Reirradiation tolerance of the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Hypofractionated stereotactic radiotherapy in the management of recurrent glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Hypofractionated reirradiation for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Fractionated stereotactic radiotherapy for skull base tumors: analysis of treatment accuracy using a stereotactic mask fixation system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Reirradiation and lomustine in patients with relapsed high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Salvage temozolomide for prior temozolomide responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-010-0446-8

The value of reoperation for recurrent glioblastoma.

21 January 2018

1 reference

12 December 2020

Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide

1 reference

12 December 2020

Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme

1 reference

12 December 2020

Stereotactic radiosurgery for recurrent malignant gliomas

1 reference

12 December 2020

Identifiers

DOI

1 reference

14 September 2017

1 reference